title: Antimigratory and antimetastatic effect of heparin-derived 4-18 unit oligosaccharides in a preclinical human melanoma metastasis model.
abstract: Heparin and its derivatives have been shown to inhibit angiogenesis and metastasis formation. Accordingly, we investigated the effect of heparin fragments containing 4 to 22 monomers on human melanoma cell proliferation, migration and invasion in vitro as well as on the in vivo metastatic potential in a SCID mouse model. Only oligosaccharide dp18 had significant inhibitory effect on cell proliferation. In contrast, cell migration was inhibited by all oligosaccharides studied except dp8 and dp22. Anti-CD44v3 antibody stimulated cell migration and invasion, and this effect could be attenuated by oligosaccharides dp4 and dp18. These fragments also inhibited the catalytic activity of myosin light chain phosphatase as well. Moreover, oligosaccharides dp4 and dp18 reduced the number of lung colonies formed in SCID mice intravenously injected with human melanoma cells, while dp22 proved to be ineffective in this respect. These studies revealed that fragments of heparin have an antimigratory and antimetastatic potential. These fragments lack the haemostatic effect of heparin, suggesting that they are potential specific antimetastatic agents in anticancer therapy.
authors: Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary.
authors: István
authors: I
authors: Kenessey
authors: Erika
authors: E
authors: Simon
authors: Krisztina
authors: K
authors: Futosi
authors: Bíborka
authors: B
authors: Bereczky
authors: Andrea
authors: A
authors: Kiss
authors: Ferenc
authors: F
authors: Erdödi
authors: John T
authors: JT
authors: Gallagher
authors: József
authors: J
authors: Tímár
authors: József
authors: J
authors: Tóvári
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D051379:Mice; D016513:Mice, SCID; D009361:Neoplasm Invasiveness; D009368:Neoplasm Transplantation; D009844:Oligosaccharides / Q000737:chemistry / Q000627:therapeutic use*; D054645:Protein Phosphatase 1 / Q000037:antagonists & inhibitors; D014183:Transplantation, Heterologous
chemical_list: D000970:Antineoplastic Agents; C497483:CD44 protein, human; D006495:Heparin, Low-Molecular-Weight; D018960:Hyaluronan Receptors; D009844:Oligosaccharides; D054645:Protein Phosphatase 1